Myriad Genetics, Inc.(MYGN) Stock Research - Grey Stern Research

Myriad Genetics, Inc. (MYGN) Stock Analysis

$9.22 (0.11%)

MYGN Financial Performance


Use the table below to view Myriad Genetics, Inc.'s financial profile. This data is gathers from the latest available financial statements. Annual data is taken from the trailing 12 months of statements. All numbers are reported in US Dollars and so any foreign currencies are converted to USD so comparison's can be done.

Based on Financial Statements from Q3 - 2024

Metric Value Ranking among Peers
Price $9.22 -
52 Week Low $9.18 -
52 Week High $29.30 -
Market Cap $841.9 Million 14/18
Gross Margin 70% 2/18
Profit Margin -10% 9/18
EBITDA margin -1% 9/18
Q3 - 2024 Revenue $213.3 Million 10/18
Q3 - 2024 Earnings -$22.1 Million 11/18
Q3 - 2024 Free Cash Flow -$5.6 Million 9/18
Trailing 4 Quarters Revenue $823.6 Million 10/18
Trailing 4 Quarters Earnings -$116.0 Million 10/18
Quarterly Earnings Growth 64% 4/18
Annual Earnings Growth 72% 5/18
Quarterly Revenue Growth 11% 7/18
Annual Revenue Growth 11% 8/18
Cash On Hand $99.9 Million 15/18
Short Term Debt $13.5 Million 10/18
Long Term Debt $129.6 Million 10/18

Myriad Genetics, Inc. Financial Metrics


Financial metrics are a set of useful numbers that can give key performance indicators of a company. The various metrics can include information about profitability, growth, and debt load. When combined and use properly they can tell an analyst a compelling fact-based story of how the company is currently performing. To compare Myriad Genetics, Inc.'s metrics versus it's peers make sure to run our peer analysis tool.

Valuation Metrics

Metric Value Ranking among Peers
PE -1.00 8/18
PS 1.02 16/18
PB 1.15 14/18
PC 8.43 13/18
Liabilities to Equity 0.48 9/18
ROA -0.11 9/18
ROE -0.16 11/18
Current Ratio 3.09 8/18
Quick Ratio 0.29 13/18
Long Term Debt to Equity 0.18 8/18
Debt to Equity 0.20 9/18
Burn Rate 3.26 8/18
Cash to Cap 0.12 6/18
CCR 0.25 11/18
EV to EBITDA -402.30 17/18
EV to Revenue 1.07 18/18

Company Details

Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, or metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, a RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, a RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. In addition, it provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, ADHD, and other mental health conditions. Myriad Genetics, Inc. has a strategic collaboration with Illumina, Inc. and Intermountain Precision Genomics for an offering of germline and somatic tumor testing services. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.

CEO: Mr. R. Bryan Riggsbee

Website: https://myriad.com

Address: 320 S Wakara Way Salt Lake City, UTAH

Exchange: NASDAQ Global Select

Industry: Diagnostics & Research

Myriad Genetics, Inc. Peer Analysis


A useful and more reliable way of seeing the health of a company is to compare it to other companies operating in the same sector. Below is our list of companies which we rank are the closest peers to Myriad Genetics, Inc.. If you feel that peers should be added or removed from this list please contact us. To run an in-depth peer analysis which compares many financial metrics click on the link below.

Stock Ticker Market Cap
CareDx, Inc CDNA $1.0 Billion
Syneos Health, Inc. SYNH $4.5 Billion
Qiagen N.V. QGEN $8.6 Billion
RadNet, Inc. RDNT $3.8 Billion
Illumina, Inc. ILMN $13.0 Billion
Exact Sciences Corporation EXAS $8.4 Billion
Invitae Corporation NVTA $5.4 Million
Medpace Holdings, Inc. MEDP $9.6 Billion
Aclaris Therapeutics, Inc. ACRS $174.8 Million
Neogen Corporation NEOG $1.9 Billion
Natera, Inc. NTRA $20.0 Billion
Castle Biosciences, Inc. CSTL $573.1 Million
Guardant Health, Inc. GH $5.6 Billion
Personalis, Inc. PSNL $316.0 Million
Twist Bioscience Corporation TWST $2.5 Billion
Sotera Health Company SHC $3.3 Billion
Olink Holding AB (publ) OLK $3.2 Billion
Run Peer Analysis
Income Statement
Balance Sheet
Cash Flow Statement
MYGN Income Statements
Quarter Year Revenue Earnings
Q3 2024 $ 213.3 Million -$22.1 Million
Q2 2024 $ 211.5 Million -$36.7 Million
Q1 2024 $ 202.2 Million -$26.0 Million
Q4 2023 $ 196.6 Million -$31.2 Million
Q3 2023 $ 191.9 Million -$61.3 Million
Q2 2023 $ 183.5 Million -$116.1 Million
Q1 2023 $ 181.2 Million -$54.7 Million
Q4 2022 $ 177.8 Million -$42.3 Million

View All

MYGN Balance Sheets
Quarter Year Cash & Equivalents Total Assets Total Debt Total Equity
Q3 2024 $99.9 Million $1.1 Billion $143.1 Million $731.7 Million
Q2 2024 $92.4 Million $1.1 Billion $143.3 Million $740.5 Million
Q1 2024 $96.9 Million $1.1 Billion $146.8 Million $760.0 Million
Q4 2023 $132.1 Million $1.1 Billion $152.1 Million $783.2 Million
Q3 2023 $76.0 Million $1.1 Billion $201.4 Million $683.4 Million
Q2 2023 $102.8 Million $1.2 Billion $203.8 Million $735.2 Million
Q1 2023 $53.6 Million $1.2 Billion $161.6 Million $835.2 Million
Q4 2022 $56.9 Million $1.2 Billion $145.0 Million $885.8 Million

View All

MYGN Cash Flow Statements
Quarter Year freeCashFlow capitalExpenditure netChangeInCash
Q3 2024 -$5.6 Million -$6.3 Million $24.8 Million
Q2 2024 -$6.3 Million -$8.9 Million -$4.4 Million
Q1 2024 -$27.2 Million -$8.6 Million -$35.3 Million
Q4 2023 -$68.2 Million -$13.5 Million $55.9 Million
Q3 2023 -$39.6 Million -$17.5 Million -$27.7 Million
Q2 2023 -$19.7 Million -$18.8 Million $49.6 Million
Q1 2023 -$56.7 Million -$23.5 Million -$3.3 Million
Q4 2022 -$22.3 Million -$14.6 Million -$44.3 Million

View All

Cookies

We use cookies to offer a better browsing experience. Cookies enhance site navigation, analyze site usage, and assist in our marketing efforts. By clicking Accept. you agree to the storing of cookies on your device. To refuse all non-required cookies, click on Decline.

Accept View Terms & Conditions